Please login to the form below
Hal Barron
This page shows the latest Hal Barron news and features for those working in and with pharma, biotech and healthcare.
GlaxoSmithKline agrees $2.2bn dementia mAb deal with Alector
neurodegenerative diseases,” said Hal Barron (pictured right), chief scientific officer and president R&D, GSK.
Latest news
-
GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug
Immuno-oncology has transformed cancer care but unfortunately less than 30% of patients respond to treatment with the current leading immune checkpoint inhibitors,” said Hal Barron, chief scientific officer and president
-
GSK, Vir’s COVID-19 mAb scores FDA emergency use approval
Hal Barron, chief scientific officer and president R&D at GSK.
-
GSK wins approval for anti-PD-1 antibody Jemperli in endometrial cancer
after first-line therapy,” said Hal Barron, chief scientific officer and president of R&D at GSK.
-
GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
GSK’s CEO Emma Walmsley and R&D chief Hal Barron have led the company’s re-entry into oncology, having overseen a number of new additions to the oncology pipeline.
-
GSK seeks EU approval for Trelegy in adult asthma patients
We believe a once-daily single inhaler triple therapy that improves lung function is an advance for patients with uncontrolled asthma since this option is not currently available,” said Hal Barron,
GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug
GSK seeks EU approval for Trelegy in adult asthma patients
More from news
Approximately 1 fully matching, plus 55 partially matching documents found.
Latest Intelligence
-
30 Women Leaders in UK Healthcare (part 3)
Walmsley has impressed with a few high-profile hirings to key positions, including Dr Hal Barron as its new R&D supremo, but it will take a few years to see
30 Women Leaders in UK Healthcare (part 3)
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Kevin Sin joins GSK
years. Dr Hal Barron, chief scientific officer and president of research and development, GSK, said: “I am extremely excited to have Kevin join GSK. ... Sin will report to Hal Barron and will be based at the group’s San Francisco office.
-
Levinson resigns from Roche board
He has served as CEO at Calico, Google's health research business, since its formation in September 2013 and has since been joined by former Genentech/Roche colleagues Hal Barron, David
-
Roche CMO joins Google health venture Calico
Hal Barron among four new appointments. Dr Hal Barron has left his role as chief medical officer of Swiss pharma company Roche to join Google's recently-launched health research arm ... Dr Barron is one of four new recruits from industry and academia to
Kevin Sin joins GSK
Levinson resigns from Roche board
Roche CMO joins Google health venture Calico
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
-
Events Executive
-
Depending on Experience
-
Digital account director
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Distracted boyfriend: the secret of a successful long-distance relationship
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- Vertex gains FDA fast track designation for diabetes stem cell therapy
- Onyx Health Launch Creative Studio After Record Year
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche appoints Philip Atkinson to new global role
- AZ’s comeback drug cediranib stumbles in phase 3 trial
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
